[Direct comparison of endothelial and metabolic effects of perindopril combination with indapamide retard or

Insights

Perindopril combined with indapamide retard showed better vascular and metabolic improvements in hypertensive patients than hydrochlorothiazide, despite similar blood pressure reduction. This suggests a potentially better long-term prognosis with indapamide retard.

Area of Science:

  • Cardiology
  • Pharmacology
  • Metabolic Health

Background:

  • Essential hypertension management requires effective blood pressure control.
  • Combination therapies are often used to achieve target blood pressure.
  • Assessing vascular and metabolic effects of different antihypertensive drug combinations is crucial for long-term patient outcomes.

Purpose of the Study:

  • To compare vascular and metabolic parameter changes in patients with essential hypertension.
  • To evaluate the effects of perindopril combined with either indapamide retard or hydrochlorothiazide.

Main Methods:

  • 40 hypertensive patients were randomized to perindopril plus indapamide retard (P+I) or perindopril plus hydrochlorothiazide (P+HT).
  • Vascular parameters (endothelial function, arterial stiffness) and metabolic parameters (lipids, glucose) were assessed at baseline and 6 months.
  • Photoplethysmography was used to measure vascular responses.

Main Results:

  • Both combinations achieved similar blood pressure reduction.
  • Perindopril plus hydrochlorothiazide significantly worsened endothelial function, triglycerides, and glucose levels.
  • Perindopril plus indapamide retard was metabolically neutral and showed a trend towards greater improvement in arterial stiffness.

Conclusions:

  • Perindopril combined with indapamide retard offers superior vascular and metabolic benefits compared to hydrochlorothiazide in hypertensive patients.
  • These findings suggest a potentially better long-term prognosis with the perindopril-indapamide retard combination.
Abstract

Related Concept Videos

Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors01:30

Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors

Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...
2.9K
Antihypertensive Drugs: Direct Renin Inhibitors01:25

Antihypertensive Drugs: Direct Renin Inhibitors

The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
1.9K
Antihypertensive Drugs: Thiazide-Class Diuretics01:15

Antihypertensive Drugs: Thiazide-Class Diuretics

Thiazide diuretics are sulfonamide derivatives featuring a benzothiadiazine ring system in their molecular structure. Based on this structure, thiazide diuretics can be categorized into two groups: thiazide-type and thiazide-like diuretics. Thiazide-type diuretics, including hydrochlorothiazide and chlorothiazide, consist of a benzothiadiazine backbone with an attached sulfonamide group. Thiazide-like diuretics, such as chlorthalidone and indapamide, lack the thiazide ring but demonstrate...
2.4K
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
1.5K
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
571
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists01:18

Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists

Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
573